Emergent BioSolutions (EBS) Net Margin (2011 - 2026)

Emergent BioSolutions' Net Margin history runs 15 years deep, the most recent figure standing at 4.36% for Q1 2026.

• In Q1 2026, Net Margin fell 2625.0% year-over-year to 4.36%; the TTM figure through Mar 2026 stood at 1.27% (up 1603.0% YoY), while the FY2025 annual figure was 7.08%, up 2534.0% from the prior year.
• Net Margin was 4.36% for Q1 2026 at Emergent BioSolutions, up from 36.72% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 39.07% in Q3 2024 to a low of 566.2% in Q2 2024.
• Historically, Net Margin has averaged 53.84% across 5 years, with a median of 17.9% in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Margin tumbled 48884 bps in 2024, then surged 55768 bps in 2025.
• A 5-year view of Net Margin shows it stood at 20.29% in 2022, then grew by 12 bps to 17.9% in 2023, then grew by 10 bps to 16.08% in 2024, then sank by 128 bps to 36.72% in 2025, then jumped by 112 bps to 4.36% in 2026.
• The last three Net Margin figures came in at 4.36% (Q1 2026), 36.72% (Q4 2025), and 22.15% (Q3 2025), per Business Quant data.